A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma

Clin Lymphoma Myeloma Leuk. 2024 Jan 24:S2152-2650(24)00055-7. doi: 10.1016/j.clml.2024.01.011. Online ahead of print.ABSTRACTIn the pivotal ZUMA-5 trial, axicabtagene ciloleucel (axi-cel; an autologous anti-CD19 chimeric antigen receptor T-cell therapy) demonstrated high rates of durable response in relapsed/refractory follicular lymphoma patients. SCHOLAR-5 is an external control cohort designed to act as a comparator to ZUMA-5. Here, we present an updated comparative analysis of ZUMA-5 and SCHOLAR-5, using the 36-month follow-up data and the intent-to-treat population of ZUMA-5. Using propensity-score methods, 127 patients in ZUMA-5 were compared to 129 patients in SCHOLAR-5. At this extended follow-up, axi-cel continues to demonstrate clinically meaningful benefits in survival compared to historically available treatments in this population.PMID:38365528 | DOI:10.1016/j.clml.2024.01.011

Source: Clinical Lymphoma and Myeloma - February 16, 2024 Category: Cancer & Oncology Authors: Paola Ghione M Lia Palomba Markqayne D Ray Eve H Limbrick-Oldfield Jessica Owen Steve Kanters Sabela Bobillo Maria Teresa Ribiero Caron A Jacobson Sattva S Neelapu Herve Ghesquieres Myrna Nahas Sara Beygi Anik R Patel John G Gribben Source Type: research